Trial reportClinical reviews in allergy & immunology2008
Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Trial report in Clinical reviews in allergy & immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review.Chinese medical journal · 2020Pooled it
- World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.Oral diseases · 2019Pooled it
- Rituximab for rheumatoid arthritis.The Cochrane database of systematic reviews · 2015Pooled it
- The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.PloS one · 2014Pooled it
- Off-label use of rituximab in systemic lupus erythematosus: a systematic review.Clinical rheumatology · 2010Pooled it
- A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.International journal of molecular sciences · 2024Review
- A 16-year-old girl with sudden heart failure and nephrotic syndrome associated with Takayasu's arteritis.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Article
- Rituximab Therapy for Primary Sjögren's Syndrome.Frontiers in pharmacology · 2021Review
- Emerging B-Cell Therapies in Systemic Lupus Erythematosus.Therapeutics and clinical risk management · 2021Review
- Refractory Takayasu arteritis successfully treated with rituximab: case-based review.Rheumatology international · 2019Review
- Outcomes of rituximab therapy in refractory lupus: A meta-analysis.European journal of rheumatology · 2018Article
- Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant.BMJ case reports · 2017Article
- The Autoimmune Ecology.Frontiers in immunology · 2016Review
- Two Takayasu arteritis patients successfully treated with rituximab.Clinical rheumatology · 2014Article
- Increased 8-hydroxy-2'-deoxyguanosine in plasma and decreased mRNA expression of human 8-oxoguanine DNA glycosylase 1, anti-oxidant enzymes, mitochondrial biogenesis-related proteins and glycolytic enzymes in leucocytes in patients with systemic lupus erythematosus.Clinical and experimental immunology · 2014Article
- Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus.Autoimmune diseases · 2014Article
- Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.Arthritis research & therapy · 2013Article
- Novel aspects of Sjögren's syndrome in 2012.BMC medicine · 2013Review
- B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.Arthritis research & therapy · 2013Review
- Whither autoimmunity: the lessons of anti-CCP and B cell depletion.Clinical reviews in allergy & immunology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 receptor present in B lymphocytes, in patients with autoimmune rheumatic diseases (AIRD). For this purpose, patients treated with RTX and their respective clinical charts were comprehensively examined. Indications for treatment were a refractory character of the disease, inefficacy or intolerance of other immunosuppressors. Activity indexes (SLEDAI, DAS28, and specific clinical manifestations) were used to evaluate efficacy. Serious side effects were also recorded. Seventy-four patients were included. Forty-three patients had systemic lupus erythematosus (SLE), 21 had rheumatoid arthritis (RA), 8 had Sjögren's syndrome (SS), and 2 had Takayasu's arteritis (TA). RTX was well-tolerated in 66 (89%) patients. In 8 patients (SLE=3, SS=3, RA=2), serious side effects lead to discontinuation. The mean follow-up period was 12+/-7.8 (2-35) months. The efficacy of RTX was registered in 58/66 (87%) patients, of whom 36 (83%) had SLE, 18/21 (85%) had RA, 3/8 (37%) had SS, and 1 had TA. The mean time of efficacy was 6.3+/-5.1 weeks. A significant steroid-sparing effect was noticed in half of the patients. These results add further evidence for the use of RTX in AIRD. Based on its risk-benefit ratio, RTX might be used as the first-choice treatment for patients with severe AIRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.